831 related articles for article (PubMed ID: 36960070)
1. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
[TBL] [Abstract][Full Text] [Related]
5. Homologous and Heterologous Covid-19 Booster Vaccinations.
Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
[TBL] [Abstract][Full Text] [Related]
6. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
7. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.
Tan CS; Collier AY; Yu J; Liu J; Chandrashekar A; McMahan K; Jacob-Dolan C; He X; Roy V; Hauser BM; Munt JE; Mallory ML; Mattocks M; Powers JM; Meganck RM; Rowe M; Hemond R; Bondzie EA; Jaegle KH; Baric RS; Schmidt AG; Alter G; Le Gars M; Sadoff J; Barouch DH
JAMA Netw Open; 2022 Aug; 5(8):e2226335. PubMed ID: 35947380
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
[TBL] [Abstract][Full Text] [Related]
9. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
[TBL] [Abstract][Full Text] [Related]
10. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
[TBL] [Abstract][Full Text] [Related]
11. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn G; Wang J; Purvis A; Ruiz MS; Adhikarla H; Alvi S; Bonaparte MI; Brune D; Bueso A; Canter RM; Ceregido MA; Deshmukh S; Diemert D; Finn A; Forrat R; Fu B; Gallais J; Griffin P; Grillet MH; Haney O; Henderson JA; Koutsoukos M; Launay O; Torres FM; Masotti R; Michael NL; Park J; Rivera-Medina DM; Romanyak N; Rook C; Schuerman L; Sher LD; Tavares-Da-Silva F; Whittington A; Chicz RM; Gurunathan S; Savarino S; Sridhar S;
EClinicalMedicine; 2023 Aug; 62():102109. PubMed ID: 37533419
[TBL] [Abstract][Full Text] [Related]
15. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
[TBL] [Abstract][Full Text] [Related]
16. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations.
Jacobsen H; Strengert M; Maaß H; Ynga Durand MA; Katzmarzyk M; Kessel B; Harries M; Rand U; Abassi L; Kim Y; Lüddecke T; Metzdorf K; Hernandez P; Ortmann J; Heise JK; Castell S; Gornyk D; Glöckner S; Melhorn V; Kemmling Y; Lange B; Dulovic A; Marsall P; Häring J; Junker D; Schneiderhan-Marra N; Hoffmann M; Pöhlmann S; Krause G; Cicin-Sain L
Sci Rep; 2022 Nov; 12(1):19858. PubMed ID: 36400804
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Roux JL; Lustig G; Madzivhandila M; Magugu SF; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
medRxiv; 2023 Nov; ():. PubMed ID: 38045321
[TBL] [Abstract][Full Text] [Related]
18. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
[TBL] [Abstract][Full Text] [Related]
19. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Le Roux J; Lustig G; Madzivhandila M; Magugu SFJ; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
PLOS Glob Public Health; 2024; 4(4):e0002703. PubMed ID: 38603677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
